Results Presented at the 17th Congress of the European Hematology Association by Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., said six-year follow-up results from a Phase 3 randomized, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec(R) (imatinib). 

The six-year data shows progression-free survival of 49.3% and an overall survival of 71% for patients randomized to dasatinib 100 mg once daily (n=167), with 6% of patients (n=10) progressing to accelerated or blast phase on study at six years of follow-up.[1] 

This November, Californians will vote on an initiative that would require any food containing ingredients derived from genetically modified crops to be labeled as such.

Backers of the “California Right To Know Genetically Engineered Food Act” are pitching it as a matter of providing information to consumers, who, they argue, “have a right to know what’s in the food we buy and eat and feed our children, just as we have the right to know how many calories are in our food, or whether food comes from other countries like Mexico or China.”

Currently, the only option for underwater energy is batteries, which shortens the amount of time an underwater system can be powered. Having a source of renewable energy underwater opens up the possibility for long-term installations of autonomous systems, including systems for communication, environmental monitoring and networks of sensors.